Protective effect of alpha‐lipoic acid and epalrestat on oxaliplatin‐induced peripheral neuropathy in zebrafish

Abstract

AbstractIntroduction/AimsOxaliplatin is a platinum‐based anti‐cancer drug widely used in colorectal cancer patients, but it may cause peripheral neuropathy. As one of the main causes of oxaliplatin‐induced peripheral neuropathy (OPN) is oxidative stress, which is also a key factor causing diabetic peripheral neuropathy (DPN), the aim of this study was to evaluate the preventive effects of alpha‐lipoic acid (ALA) and epalrestat (EP), which are used for the treatment of DPN, in an OPN zebrafish model.MethodsTg(nbt:dsred) transgenic zebrafish, with sensory nerves in the peripheral lateral line, were treated with oxaliplatin, oxaliplatin/EP, and oxaliplatin/ALA for 4 days. A confocal microscope was used to visualize and quantify the number of axon bifurcations in the distal nerve ending. To analyze the formation of synapses on sensory nerve terminals, quantification of membrane‐associated guanylate kinase (MAGUK) puncta was performed using immunohistochemistry.ResultsThe number of axon bifurcations and intensity of MAGUK puncta were significantly reduced in the oxaliplatin‐treated group compared with those in the embryo medium‐treated group. In both the oxaliplatin/EP and oxaliplatin/ALA‐treated groups, the number of axon bifurcations and intensity of MAGUK puncta were greater than those in the oxaliplatin‐treated group (p < .0001), and no significant difference was observed between larvae treated with oxaliplatin/ALA 1 μM and oxaliplatin/EP 1 μM (p = .4292).DiscussionALA and EP have protective effects against OPN in zebrafish. Our findings show that ALA and EP can facilitate more beneficial treatment for OPN.